胆道癌中的遗传性癌症变异与同源重组缺陷
该研究对1292例胆道癌病例和37583例无癌症个人及家族史对照进行27个致癌基因的胚系变异测序,发现5.5%的胆道癌病例携带至少一个致病性胚系变异,BRCA1、BRCA2、APC和MSH6变异在胆道癌中富集。对45例胆道癌组织进行全基因组测序显示,BRCA2和PALB2致病性胚系变异伴杂合性缺失的胆道癌呈现同源重组缺陷表型。
要点
- 5.5%的胆道癌病例携带至少一个致病性胚系变异,BRCA1、BRCA2、APC和MSH6变异显著富集。
- BRCA2和PALB2致病性胚系变异伴杂合性缺失的胆道癌显示同源重组缺陷。
- 无第二次打击的同源重组相关基因变异或ATM、BRIP1等其他基因变异显示同源重组功能正常表型。
核心结论
- 本研究描述了同源重组相关基因变异的可遗传性和可干预性,可用于指导胆道癌的筛查和治疗策略。
- 同源重组相关基因的双重打击是产生同源重组缺陷表型所必需的。
- PARP抑制剂和DNA损伤方案可能对呈现同源重组缺陷的胆道癌有效。
研究设计与样本
- 对1292例胆道癌病例和37583例无癌症个人及家族史对照进行27个致癌基因的胚系变异测序。
- 比较病例与对照之间致病性胚系变异频率,并记录携带者的人口学和临床特征。
- 对45例胆道癌组织进行全基因组测序以评估同源重组缺陷状态。
主要发现
- 靶向测序共鉴定5018个胚系变异,分类为317个致病性变异、3611个意义不明变异和1090个良性变异。
- 71例胆道癌病例(5.5%)在27个致癌基因中携带至少一个致病性变异。
- 在胆道癌中富集的致病性胚系变异见于BRCA1、BRCA2、APC和MSH6(p <0.00185)。
- PALB2变异与胆道癌的关联为边缘性(p = 0.01),APC变异主要见于法特壶腹癌。
- 全基因组测序显示3例携带BRCA2和PALB2致病性胚系变异伴杂合性缺失的胆道癌呈现同源重组缺陷;无第二次打击的致病性胚系变异或ATM、BRIP1等其他同源重组相关基因变异显示同源重组功能正常表型。
临床怎么用
- 作者认为PARP抑制剂和DNA损伤方案可能对呈现同源重组缺陷的胆道癌有效。
- 作者认为同源重组相关基因变异的可遗传性和可干预性可用于指导胆道癌的筛查和治疗策略。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: The heritability and actionability of variants in homologous recombination-related genes in biliary tract cancers (BTCs) are uncertain. Although associations between BTC and BRCA germline variants have been reported, homologous recombination deficiency has not been investigated in BTCs. METHODS: We sequenced germline variants in 27 cancer-predisposing genes in 1,292 BTC cases and 37,583 controls without a personal nor family history of cancer. We compared pathogenic germline variant frequencies between cases and controls and documented the demographic and clinical characteristics of carriers. In addition, whole-genome sequencing of 45 BTC tissues was performed to evaluate homologous recombination deficiency status. RESULTS: Targeted sequencing identified 5,018 germline variants, which were classified into 317 pathogenic, 3,611 variants of uncertain significance, and 1,090 benign variants. Seventy-one BTC cases (5.5%) had at least one pathogenic variant among 27 cancer-predisposing genes. Pathogenic germline variants enriched in BTCs were present in BRCA1, BRCA2, APC, and MSH6 (p <0.00185). PALB2 variants were marginally associated with BTC (p = 0.01). APC variants were predominantly found in ampulla of Vater carcinomas. Whole-genome sequencing demonstrated that three BTCs with pathogenic germline variants in BRCA2 and PALB2, accompanied by loss of heterozygosity, displayed homologous recombination deficiency. Conversely, pathogenic germline variants without a second hit or variants of other homologous recombination-related genes such as ATM and BRIP1 showed homologous recombination-proficient phenotypes. CONCLUSIONS: In this study, we describe the heritability and actionability of variants in homologous recombination-related genes, which could be used to guide screening and therapeutic strategies for BTCs. IMPACT AND IMPLICATIONS: We found that 5.5% of biliary tract cancers (BTCs) in a Japanese population possessed hereditary cancer-predisposing gene alterations, including in BRCA and genes associated with colorectal cancer. Two hits in homologous recombination-related genes were required to confer a homologous recombination-deficient phenotype. PARP inhibitors and DNA-damaging regimens may be effective strategies against BTCs exhibiting homologous recombination deficiency. Hence, in this study, genome-wide sequencing has revealed a potential new therapeutic strategy that could be applied to a subset of BTCs.
引用
- Okawa Y, Iwasaki Y, Johnson TA, et al. Hereditary cancer variants and homologous recombination deficiency in biliary tract cancer. J Hepatol. 2022. PMID: 36243179. doi:10.1016/j.jhep.2022.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。